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Cutaneous Gene Expression by DNA Microarray in
Murine Sclerodermatous Graft-Versus-Host Disease,
a Model for Human Scleroderma
Lixin Zhou1, David Askew1, Caiyun Wu1 and Anita C. Gilliam1
The molecular mechanisms governing skin fibrosis in murine sclerodermatous graft-versus-host disease (Scl
GVHD) are not known. We used Affymetrix DNA microarrays representing 414,000 mouse genes to
characterize global gene expression in skin during development of Scl GVHD in lethally irradiated BALB/c
(H-2d) mice transplanted with B10.D2 (H-2d) bone marrow and spleen cells. These mice develop skin thickening,
whereas control mice transplanted with syngeneic BALB/c (H-2d) bone marrow and spleen cells do not develop
disease. We found consistent differences between mice with Scl GVHD and controls in cytokine messenger
RNAs (mRNAs) for both Th1-like (IFN-g) and Th2-like (IL-6, Il-10, and IL-13) inflammatory patterns. mRNAs for
chemokines CCL2, CCL5, CCL17, IFN-g inducible chemokines (CXCL9/Mig, CXCL10/IP-10, and CXCL11/I-TAC),
and for growth factors such as platelet-derived growth factor-c, connective tissue growth factor, fibroblast
growth factor 1, epidermal growth factor, nerve growth factor-b, vascular endothelial growth factor (VEGF)-a,
and VEGF-b were elevated, similar to human scleroderma. mRNAs for cell adhesion molecules, such as
L-selectin (selectin lymphocyte), P-selectin (selectin platelet), E-selectin (selectin endothelium), and vascular cell
adhesion molecule 1, were also upregulated. In separate experiments, we confirmed the increased synthesis of
IFN-g and IL-2, unchanged IL-10, and absence of tumor necrosis factor-a, and IL-4 proteins by flow cytometry of
isolated skin T cells. These constellations of immunologic changes provide a ‘‘fingerprint’’ for fibrosing
autoimmune disease. They are useful to understand the pathogenesis of Scl GVHD, to identify markers for early
diagnosis of disease, and to devise more effective strategies for intervention in early scleroderma and Scl
GVHD.
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INTRODUCTION
Systemic sclerosis is a chronic autoimmune connective tissue
disease characterized by skin thickening and visceral fibrosis
of internal organs owing to abnormal accumulation of
extracellular matrix (Derk and Jimenez, 2003; Sakkas,
2005). Histological analysis of the initial stage of scleroderma
shows a perivascular infiltrate of mononuclear cells in the
dermis, associated with abnormal synthesis and degradation
of collagen (Fleischmajer, 1977). Much of the published work
on scleroderma is derived from studies of fibroblasts cultured
from skin biopsies of scleroderma patients with long-standing
disease or from autopsy specimens. Early pathology of the
disease is not as well understood because early scleroderma
is subtle clinically. Diagnosis depends on the documentation
of tissue fibrosis and on a constellation of clinical findings,
and as a result, the diagnosis of scleroderma is often delayed
until late in the course of disease, when therapies are not
effective. A challenge in the development of effective
therapies for scleroderma is to identify markers which are
characteristic of early scleroderma, and which are critical for
disease initiation and progression. We hypothesize that there
are key immune and matrix abnormalities that occur in early
scleroderma that may be good targets for diagnosis and
therapy in early fibrosing disease.
We have characterized a murine model that recapitulates
many features of human scleroderma (McCormick et al.,
1999; Zhang et al., 2002; Gilliam, 2004). In this model,
irradiated BALB/c (H-2d) mice transplanted across minor
histocompatibility loci with B10.D2 (H-2d) bone marrow and
spleen cells develop skin thickening and lung fibrosis, along
with cutaneous immune cell infiltrates, transforming growth
factor (TGF)-b1 overproduction, and upregulation of cuta-
neous collagen synthesis by RNase protection assay. This
fibrosing form of graft-versus-host disease (GVHD), sclero-
dermatous GVHD (Scl GVHD), is quite different from acute
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cytotoxic GVHD, which resembles lupus erythematosus and
is characterized by ‘‘dermatitis, hepatitis, and diarrhea’’.
Murine Scl GVHD resembles explosive scleroderma that
progresses over months rather than years. Measurable skin
thickening occurs within 3 to 5 weeks after bone marrow
transplantation (BMT). Control mice transplanted with BALB/
c bone marrow and spleen cells do not develop skin
thickening or GVHD. Therefore, this mouse model of
autoimmune fibrosis holds great promise for identifying early
molecular markers for the disease, for understanding the patho-
genesis of scleroderma and for developing new treatments for
scleroderma and GVHD.
We used DNA microarrays to profile mouse global gene
expression in skin during the early and late stages of Scl
GVHD. We compared the patterns of gene expression in Scl
GVHD mice with control mice during progression of the skin
thickening from days 7, 30, 60, and 120 post-BMT. Here, we
report the sequential messenger RNA (mRNA) patterns of
several important immunologic parameters governing early
Scl GVHD, focusing on molecules known to be important in
scleroderma, as well as novel molecules not previously
implicated in scleroderma. Although we reconfirmed certain
cytokines by reverse transcriptase (RT)-PCR and flow
cytometry at the protein level, we present these data with
the caveat that mRNA expression may not always reflect
protein expression, which must be confirmed separately. We
found a mixed Th1/Th2-like cytokine mRNA profile that
changes over time from Th1 predominant to Th2 predomi-
nant, and increased mRNA for chemokines for T cells and
macrophages (CCL2, CCL5, and CCL17) and for IFN-g
inducible CXC chemokines. These data complement our
previous in vivo and in vitro studies of immune cell activation
and the cytokine and chemokine microenvironments in skin
by RT-PCR analysis and flow cytometry analysis in murine Scl
GVHD (Gilliam, 2004). Certain cell adhesion molecules
were also identified as potential new markers for early
fibrosing autoimmune disease.
RESULTS
Clinical findings and histology of Scl GVHD
Lethally irradiated BALB/c mice transplanted with bone
marrow and spleen cells from B10.D2 mice (Scl GVHD
mice) show a chronic dermatitis on the ears, around the eyes,
and on the back that eventually causes alopecia by day 35
post-BMT in Figure 1a (top panel), whereas BALB/c mice
transplanted with cells from BALB/c mice (BMT control mice)
do not show hair loss (Figure 1a, bottom panel). Serial body
weights (Figure 1b) indicate that initial body weight loss and
failure to gain weight are sensitive indices of Scl GVHD.
Routine histologic sections of back skin were examined for
the presence of inflammatory cells and skin thickness. Shown
are images from days 7, 30, 60, and 120 post-BMT (Figure 2,
top panels). Histopathological changes in skin include
transient decreased subcutaneous fat, an influx of mono-
nuclear cells with many macrophages deep in the dermis,
and increased skin thickening in experimental but not BMT
control mice. Over the course of disease the amount of skin
thickening peaks by 60 days and begins to return to normal
thickens although the dermis appears denser by day 120 post-
BMT (Figure 2, bottom panels). During the early 1–2 weeks of
disease, much of the thickening appears to be due to
inflammation and edema; however at later points, the dermal
thickness is due to connective tissue accumulation. Epidermis
is also thickened at later time points (see the image of Scl
GVHD at day 60 post-BMT).
Overview of gene expression profiles
DNA microarray analysis was performed on total RNA from
the identical topographical location on the dorsum of one
representative mouse from each group of experimental Scl
GVHD and BMT control mice on days 7, 30, 60, and 120
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Figure 1. Mice on day 35 after BMT. (a) BALB/c mice transplanted with bone
marrow and spleen cells from B10.D2 mice (Scl GVHD) show a chronic
dermatitis on the ears, around the eyes, and on back and develop patchy
alopecia (upper panel). BALB/c mice transplanted with cells from BALB/c
mice (BMT control) do not show dermatitis or hair loss (lower panel). (b) Serial
body weights (g) of mice by week after BMT. Normal mice (unirradiated
littermate mice without BMT transplantation), lethally irradiated BALB/c mice
transplanted with bone marrow and spleen cells from B10.D2 mice (Scl
GVHD), BALB/c transplanted with cells from BALB/c mice (control mice)
were compared. Five mice were in each group at the beginning of the
experiments. As mice were killed at each time point, there was only one
mouse in each group at day 120 after BMT.
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post-BMT and corrected to a normal BALB/c mouse (normal
skin) that had not been irradiated or transplanted. Gene or
probe sets meeting the inclusion criteria of at least a 2-fold
difference between comparison groups at any of the four time
points were subjected to one-way hierarchical clustering
(data not shown). This analysis revealed that experimental
and BMT control groups exhibit a clear difference in the
overall cutaneous gene expression profiles at each time point.
The most dramatically upregulated genes (standardized
signal fold change) in murine Scl GVHD versus BMT control
are presented in Table 1 and the most dramatically down-
regulated genes are presented in Table 2. Many of those
genes in the tables are related to transcription and translation,
and to cell cycle pathways, which could be seen in many
other inflammatory processes. Keratin and keratin-related
protein mRNA expression were found downregulated on day
30 after BMT in murine Scl GVHD. Because of our interest in
the immunology of early fibrosing disease in skin, we focused
on the following markers: chemokines and their receptors,
cytokines, growth factors, and adhesion molecules, which are
bolded in the tables.
We have previously reported certain major cytokine and
chemokine-related gene expression by RT-PCR (McCormick
et al., 1999; Zhang et al., 2002).
Cytokines
Microarray gene expression data for major cytokines in Scl
GVHD and BMT control are presented in Table 3. mRNAs for
IFN-g, tumor necrosis factor (TNF)-b, IL-6, IL-10, IL-13, IL-18,
and TGF-b1 were upregulated in Scl GVHD mice. IL-4 was
unchanged. IFN-g mRNA expression level was markedly
elevated on day 7, and reduced but still elevated over BMT
control on day 60. TNF-b mRNA expression reached a peak
at day 30. TGF-b1 mRNA increased by modest amounts (4–5-
fold over BMT control), similar to our previously published
results by semiquantitative RT-PCR (Zhang et al., 2002). We
analyzed major cytokine proteins from single cell suspen-
sions of skin T cells on day 7 post-BMT (Figure 3). In the skin
of mice with Scl GVHD, IFN-g, and IL-2 are upregulated and
no Il-4 is detectable. Also, TNF-a and IL-10 are the same or
less than in BMT controls, similar to gene array results.
Chemokines and their receptors
Microarray gene expression data for chemokines and their
receptors in skin are presented in Table 4. mRNAs for
chemokines CCL1, CCL2 monocyte chemoattractant protein
(MCP-1), CCL3, CCL4, CCL5 (RANTES), CCL7 (MCP-3),
CCL9 (macrophage inflammatory protein-1g), CCL11 (eotax-
in), CCL12 (MCP-5), CCL 17 (thymus- and activation-
regulated chemokine), CCL19 (macrophage inflammatory
protein-3b), CCL21, CCL22 (MDC), CXCL1, CXCL2, CXCL5
(ENA-78), CXCL7, CXCL9 (MIG), CXCL10 (IP-10), and
CXCL11 (I-TAC) were upregulated in Scl GVHD mice
compared with the BMT control mice. High levels of
chemokine mRNAs from day 7 to day 120 were seen for
CCL2 (MCP-1), CCL5 (RANTES), CCL17, and IFN-g inducible
chemokines (CXCL9/Mig, CXCL10/IP-10, CXCL11/I-TAC),
which are all monocyte/macrophage and T-cell related. In
general, these tended to be initially high, and then decreased
with time. Chemokine receptor mRNAs CCR1, CCR5,
CXCR6, CCR7, and CCR9 were increased in Scl GVHD mice.
Growth factors
We examined mRNA expression for several well known
growth factors previously reported to be associated with
human scleroderma, such as platelet-derived growth factor
(PDGF)-C, connective tissue growth factor (CTGF), fibroblast
growth factor 1, epidermal growth factor, nerve growth
factor-b, vascular endothelial growth factor (VEGF)-a, VEGF-
b, and related receptors in Table 5. The earliest mRNAs to be
upregulated in skin of Scl GVHD mice were for fibroblast
growth factor 1 and epidermal growth factor, increased by
2-fold over BMT control mice on day 7 after BMT. Increased
PDGF-C, and VEGF mRNA seem most closely correlated
with increasing skin thickness by day 30, whereas CTGF
mRNA is increased by approximately the amount as in BMT
control mice.
Cell adhesion molecules
Microarray gene expression data for adhesion molecule-
related genes are presented in Table 6. L-selectin (selectin
lymphocyte) was up regulated in Scl GVHD mice, P-selectin
(selectin platelet), E-selectin (selectin endothelium) also had
higher expression in Scl GVHD mice although some increase
was also seen in control mice. Integrin alpha, ICAM 1, and
vascular cell adhesion molecule 1 mRNAs were also
upregulated in Scl GVHD mice. mRNAs for cadherin 5 and
13 were downregulated compared to control.
BMT control
BMT control
Scl GVHD
Scl GVHD
Day post BMT 7
Day 120 post BMT 7
30 60 120
Figure 2. Routine histology of back skin from mice with Scl GVHD and BMT
control on days 7, 30, 60, and 120 after BMT. Each panel shows the skin of
the representative mouse selected for gene array studies. There is transient
decreased subcutaneous fat, an influx of mononuclear cells, and increased the
skin thickening that peaks at 30–60 days and begins to decline after BMT in
Scl GVHD mice (top two panels, 10 ). Skin thickening is less apparent by
day 120 in Scl GVHD mice; however, the dermis is denser in appearance
(lower panel  40). Bar¼100 mm.
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DISCUSSION
We have previously used the murine Scl GVHD model to
characterize critical cell types, cytokines, and chemokines
in early autoimmune fibrosing disease (McCormick et al.,
1999; Zhang et al., 2002; Gilliam, 2004). Before day 21,
increased cutaneous monocyte/macrophages and T cells are
seen by immunostaining and flow cytometric analysis of skin
single cell suspensions. CD11bþ macrophages expressing
scavenger receptors predominate over CD3þ T cells. The
immune cells infiltrating skin in Scl GVHD mice include
those of donor origin (Zhang et al., 2002). Lethally irradiated
BALB/c mice transplanted with bone marrow and spleen cells
from B10.D2 mice show a chronic dermatitis on the ears,
around the eyes and on the back that eventually causes
patchy alopecia by day 35 after BMT, whereas BMT control
mice transplanted with cells from syngeneic BALB/c mice do
not show hair loss. Serial body weights indicate that body
weight is a sensitive index of Scl GVHD with Scl GVHD mice
failing to gain weight compared with normal and BMT
control mice. The BMT control mice show a weight
intermediate between normal mice and Scl GVHD mice. In
addition, mRNAs for cutaneous C-C chemokines MCP-1,
macrophage inflammatory protein-1a, and RANTES are
increased at early time points (day 7, 14, and 21 after BMT)
by semiquantitative RT-PCR analysis (Zhang et al., 2002),
Cytokines IFN-g, IL-2, and IL-10 and can be detected in
isolated skin T cells by flow cytometry analysis, validating our
gene array data.
By using DNA microarrays representing 414,000 mouse
genes, we studied gene expression patterns in skin during the
early and late stages of murine Scl GVHD at days 7, 30, 60,
and 120 representing different stage of fibrosis determined by
histopathological changes. We find clear differences in gene
expression between the Scl GVHD and BMT control mice at
each time point. The kinetics of gene expression are
consistent with skin disease progression, reflecting early
influx of immune cells, particularly macrophages and T cells,
and upregulation of cytokine and chemokine mRNAs,
particularly mRNAs for certain adhesion molecules, which
could reflect immune cell–matrix interaction.
Table 1. The most dramatically upregulated genes in Scl GVHD versus BMT control by signal
Day 7 Fold Day 30 Fold Day 60 Fold Day 120 Fold
Small proline-rich
protein
274.4 Small proline-rich
protein
724.8 Small proline-rich
protein
1,097.5 Pan hematopoietic
expression (phemx)
207.9
RIKEN cDNA
2610528A11
104 Tripartite motif 337.70 Ig lambda chain 362 Chitinase-3 78.9
Histocompatibility 28 73.5 Pan hematopoietic
expression (phemx)
294.7 Lysophospholipase 3 294 Expressed sequence
a1447904
24
CXCL 5 52 Lysophospholipase 3 157.9 Tripartite motif
protein12
194 Ovary testis transcribed 21
Melanoma-derived
leucine zipper
42.2 PRKA anchor protein 128 Bromodomain adjacent
to zinc finger
194 Ig joining chain 19.75
Chitinase-3 39.4 CXC R6 119.43 Ig heavy chain 181 CXC R7 17.75
Macrophage scavenger R 34.3 Immunoresponsive gene 1 118 Kinesin 2 157 Ig heavy chain 14
Suppressor of
K+ Transport
34.3 Class II transactivator 97 CXC R6 137 Potassium intermediate
ion channel
14
Granzyme B 32 Calpain 1 84 Calpain 1 137 Unknown 13
CXCL11 32 RIKEN 78.9 Ig kappa chain 128 CXCL2 11.31
Alphafetoprotein 29.9 Ig lambda chain 68.5 Guanine nucleotide
binding protein
119 Preferentially expressed
antigen
11.31
Matrix metalloproteinase 27.9 Pore-forming protein 64 Pan hematopoietic
expression (phemx)
119 Ig heavy chain 9.3
CXCL10 26 IFN consensus binding
protein
64 Neutrophil cytosolic
factor 1
119 Mus musculus similar
to protease
9.19
Galactosyltransferase 26 Lymphocyte activation
gene 3
64 Sphingosine phosphate
Lyase 1
111 Peptide YY 8.57
CXCL R6 24.3 SLAM 8 64 CAP 97 Unknown 8
Serum amyloid A1 24.3 RIKEN cDNA 2610507 64 TGF-b receptor 1 84 IL-6 7.46
Endothelin enzyme 1 24.3 Programmed cell death 1 64 Heat-shock protein 7 78 Sorting nexin 6 6.96
CXC R5 22.6 Killer cell R 64 Stomatin 73 Ig kappa chain 6.96
Anhydrase 4 21.1 Sorting nexin 6 59 Solute carriers 2 73 CD244 6.99
CXCL9 21.1 IFN-g 59 Ig joining chain 68 RIKEN cDNA 6.5
1BMT, bone marrow transplantation; cDNA, complementary DNA, Scl GVHD, sclerodermatous graft-versus-host disease; TGF, transforming growth factor.
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Cytokines
Cytokines are the soluble mediators of immune activation,
altered fibroblast proliferation and extracellular matrix
accumulation in scleroderma (Derk and Jimenez, 2003).
Th1/Th2: An imbalance between the type-1 and type-2
cytokines may be important in the pathogenesis of sclero-
derma (Denton and Abraham, 2004). Increased secretion of
IFN-g has been demonstrated in the early phase of cytotoxic
GVHD (Hu et al., 1999; Ferrara et al., 2003) in humans and
mice. IFN-g is also a prominent cytokine in the early phase of
murine Scl GVHD, confirmed by semiquantitative RT-PCR
analysis of total skin RNA on day 21 (Zhang et al., 2002) and
in these gene array data. As IL-6, IL-10, IL-13 mRNAs are also
increased in Scl GVHD by gene array analysis, there is a
mixed Th1/Th2-like cytokine profile in early fibrosis with a
Th1-like predominance early and Th2-like profile later (see
IFN-g/IL-10 ratio in Table 3). However, IL-18 may play a key
role in promoting Th1 T-cell development in the absence of
IL-12 in this Scl GVHD model. At later time points after
disease is established, the Th1/Th2 cytokine mRNA profile
changes to Th2 predominant. The trend is generally down
for cytokine mRNAs, suggesting that disease enters a non-
inflammatory phase at approximately day 60 post-BMT.
IFN-g: IFN-g has also been documented in scleroderma
skin, a paradoxical finding as IFN-g inhibits fibroblast
collagen synthesis in vitro (Ghosh et al., 2001). IFN-g may
function in vivo in an immune regulatory role in fibrosing
disease. TNF-b enhances IFN-g function and may be
important in mediating chronic inflammation.
IL-13: IL-13 mRNA expression is not present at later points
in Scl GVHD, which correlates with the function of IL-13
in suppressing proinflammatory monocyte/macrophage cyto-
kine production.
Il-4: Also notable is the absence of IL-4 mRNA changes in
both microarray and flow cytometry studies. IL-13 may be
more important than Il-4 for fibrosis in this model, mainly
very early in disease. Unlike the tight skin mouse mouse
(Siracusa et al., 1996), Il-4 is not a major cytokine in skin in
the Scl GVHD mouse. The tight skin mice have a mutation in
the regulation of DNA-binding proteins for collagen and
Table 2. The most dramatically downregulated genes in Scl GVHD versus BMT control by signal
Day 7 Fold Day 30 Fold Day 60 Fold Day 120 Fold
Hemoglobin alpha 111 RIKEN cDNA 2310043 11,585 Distalless homeo-box1 73 CD209b 84
Microfibrillar protein 4 111 Keratin-associated protein 13-1 7,131 RIKEN cDNA 1110032 39 MUS 5048294 16
Metallothionein 4 32 Keratin-associated protein
16-10
6,208 Keratin-associated
protein 16-1
34 RIKEN cDNA 2310066 12
Guanine nucleotide
binding protein
24.3 Keratin-associated protein 15 4,705 Potassium voltage gated
channel
29 Eosinophil-associated
protein
8
G1–S transition 12.1 Keratin-associated protein 6-3 4,705 Keratin-associated
protein 16-2
27 CD209d 7.4
Stearoyl-coenzyme
desaturase 1
11.3 Keratin-associated protein 16-2 4,705 Keratin-associated
protein 6-3
27 Paired-Ig-like receptor 6.9
Retinol binding protein 11.3 Keratin-associated protein 6-1 4,096 Atonal homolog 26 Hepcidin antimicrobial 4.9
Secretoglobin 9.2 Keratin-associated protein 16-7 3,821 Secretin 26 Phospholipase A2 4
Thyroid responsive
spot14
8.6 Keratin-associated protein16-5 3,821 Carboxypeptidase Z 26 TGF-b receptor II 4
Cross hyb maching
probes
8.6 Keratin-associated protein 16-8 3,565 RIKEN cDNA 110032 26 Protein tyrosine
phosphatase
3.7
Involucrin 8 Keratin-associated protein 8-1 3,104 RIKEN 6330512 16 CD163 antigen 3.4
Acetyl-coenzyme
synthetase
8 Keratin-associated 16-1 2,896 Suppressor variegation
3
16 Prostglandin F receptor 3.2
T-cell lymphoma
Metastasis 2
8 Keratin complex 2 basic gene 10 2,194 Crystallin, mu 5 Histidine ammonia
lyase
3.2
Fatty acid synthase 7 Keratin-associated protein 6-2 2,048 Keratin-associated
protein 6-1
12 Sec61 alpha1 3.2
Glutathione S-
transferase
7 Keratin complex 2 basic gene 18 1,552 Keratin-associated
protein 6-2
12 Cytochrome P450 3.2
Deleted in polyposis 1 7 RIKEN cDNA 4631426 1,552 Keratin complex 2 basic
gene10
11 CD209a antigen 3
Glycogen synthase 7 Keratin complex acidic gene 1 1,552 RIKEN cDNA 5530401 11 Aquaporin 9 3
Integrin beta 1 7 RIKEN 1110032 1,448 Hemeo box 11 F-box domain 3
1BMT, bone marrow transplantation; cDNA, complementary DNA; Scl GVHD, sclerodermatous graft-versus-host disease; TGF, transforming growth factor.
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matrix protein expression (Kielty et al., 1998), suggesting a
pathophysiology that is quite different than this Scl GVHD
mouse model. There may be multiple different pathways to
the end stage of tissue fibrosis, according to these differences.
TGF-b: Obviously, as a major fibrogenic cytokine, TGF-b1
plays an important role in the murine Scl GVHD model,
similar to human scleroderma. TGF-b1 function may be
heterogeneous, and function may depend on the level in skin.
In the absence of inhibitory signals, fibrogenic cytokine
overexpression could sustain the connective tissue accumu-
lation, which results in permanent alteration in tissue
structure and function (Sakkas, 2005). The TGF-b mRNA
fold increase (2–5-fold) by gene array is similar to our
previously published RT/PCR results (McCormick et al.,
1999). The keratin gene mRNA downregulation (Table 2)
agrees with TGF-b1 upregulation, as TGF-b1 is a known
inhibitor of epithelial proliferation. However, the increased
epidermal thickness histologically (Figure 2a, middle panel,
days 30 and 60 post-BMT) suggests increased proliferation, a
paradoxical finding for which we have no explanation at
present.
Chemokines and chemokine receptors
Chemokines and their receptors have been implicated in the
pathogenesis of scleroderma (Atamas and White, 2003). By
recruiting immune cells to target tissues, they are essential
contributors to tissue damage. Chemokines identified in
human scleroderma such as CCL2 (MCP-1), CCL3 (macro-
phage inflammatory protein-1a), CCL5 (RANTES), CCL7
(MCP-3), and cytokines which can also act as chemokines
(IL-8 and TGF-b), act through numerous pathways and
mechanisms to affect inflammatory cell attraction to skin,
Table 3. Cytokine mRNA expression in standardized signal in skin after BMT
BMT control Scl GVHD
Days after BMT 7 30 60 120 7 30 60 120
Th-1 like cytokines
IL-2 0 0 0 0 0 40 0 0
IFN-g 0 0 0 0 279 194 170 0
TNF-b 0 0 0 0 147 368 187 73
Th-2 like cytokines
IL-4 0 0 0 0 0 0 0 0
IL-5 0 0 0 0 0 0 0 0
IL-6 40 52 54 17 332 163 75 155
IL-10 49 30 31 38 11 156 51 56
IL-13 0 0 0 0 79 0 0 0
Others
IL-12 0 0 0 0 0 0 0 0
IL-18 535 574 560 528 1,845 1,819 1,619 539
TGF-b1 0 82.7 88 166 301 408 427 124
IFN-g/IL-10 — — — — 25.36 1.24 2.98 0
1BMT, bone marrow transplantation; mRNA, messenger RNA; Scl GVHD, sclerodermatous graft-versus-host disease; TGF, transforming growth factor; TNF,
tumor necrosis factor.
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Figure 3. Cytokine expression by T cells isolated from skin at day 7 post-BMT. Single cell suspensions of skin cells were cultured on anti-CD3-coated plates
in the presence of 1 mg/ml brefeldin A to isolate T cells. Adherent cells were then stained with fluorescently labeled anti-CD4 antibody, washed, fixed, and
permeabilized with saponin to allow intracytoplasmic staining by antibodies. After incubation with fluorescent anticytokine antibodies or isotype control
antibodies, cells were washed and examined by flow cytometry analysis for intracellular cytokine protein expression. Grey plot: isotype control; thin line
plot: BMT control mice; thick line plot: mice with Scl GVHD. The numbers in the right upper panel represent % positive cells detected with a particular
anticytokine antibody as follows: BMT control (normal font) and Scl GVHD (bold font).
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Table 4. Chemokine mRNA expression in standardized signal in skin after BMT
BMT control Scl GVHD
Days after BMT 7 30 60 120 7 30 60 120
CCL1 0 0 0 0 294 0 0 0
CCL2 (MCP-1) 749 236 227 154 8,332 2,192 922 442
CCL3 (MIP-1a) 0 0 0 0 99 499 279 37
CCL4 (MIP-1b) 0 0 0 0 0 502 237 103
CCL5 (RANTES) 0 202 198 0 1,820 3,908 1,178 311
CCL6 6,557 2,291 2,316 2,447 11,255 9,759 8,242 3,780
CCL7 (MCP-3) 814 297 221 241 7,642 2,121 867 463
CCL8 (MCP-2) 16,892 9,491 9,441 8,969 15,909 14,302 13,423 7,479
CCL9, 10 3,612 1,898 1,756 1,738 9,765 7,812 5,565 2,683
CCL11 (Eotaxin) 1,376 507 408 358 5,048 2,360 1,556 553
CCL12 (MCP-5) 959 456 444 344 4,797 1,997 1,499 608
CCL17 (TARC) 377 0 0 0 708 137 304 0
CCL19 (MIP-3b) 642 0 0 0 1,998 0 0 0
CCL20 0 0 0 0 0 0 0 0
CCL21 2,968 756 777 908 3,195 2,825 2,588 1,035
CCL22 (MDC) 0 0 0 27 136 82 74 27
CCL24 781 219 263 332 1,027 249 274 141
CCL25 0 0 64 70 0 38 0 36
CCL27 0 0 0 0 0 0 0 0
CCL28 16 0 0 0 22 13 0 0
CXCL1 129 155 158 122 705 348 242 280
CXCL2 66 34 10 11 99 251 82 175
CXCL4 394 162 155 137 305 84 193 117
CXCL5 0 0 0 0 169 18 19 0
CXCL7 0 0 0 33 0 77 110 86
CXCL9 710 584 234 101 8,704 7,668 4,568 756
CXCL10 171 405 158 143 4,340 1,974 945 191
CXCL11 130 146 28 0 3,217 647 304 82
CXCL12 746 519 760 770 521 355 390 601
CXCL13 500 182 222 321 475 567 753 215
CXCL14 174 1,272 1,253 1,577 440 379 616 1,446
CXCL15 0 0 0 0 0 0 0 0
CXCL16 208 127 107 81 291 881 493 142
CXCL1 0 0 0 0 0 0 0 0
CCR1 204 119 112 111 1,961 882 581 173
CCR2 104 200 178 103 62 335 249 211
CCR3 0 0 0 0 0 0 0 0
CCR4 0 0 0 0 0 0 0 0
CCR5 38 32 22 37 619 485 322 66
CCR6 110 33 20 25 0 34 105 33
CCR7 0 0 0 0 0 76 40 30
CCR9 0 0 0 0 0 33 38 0
CXCR3 161 80 88 57 321 244 244 77
CXCR6 0 0 0 0 321 235 199 40
1BMT, bone marrow transplantation; mRNA, messenger RNA; Scl GVHD, sclerodermatous graft-versus-host disease; MCP, monocyte chemoattractant
protein; MIP, macrophage inflammatory protein.
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directly stimulate target cells and induce fibrosis and vascular
injury (Derk and Jimenez, 2003). We observed increased
mRNA expression of those chemokines and cytokines already
identified in scleroderma (Zhang et al., 2002), thus validating
the gene array data in this murine model. We also identified
an additional chemokine (CCL17, thymus- and activation-
regulated chemokine), as one of the most highly expressed
genes other than CCL5 (RANTES) in the murine Scl GVHD
model. Thymus- and activation-regulated chemokine/CCL17
is an 8-kDa CC chemokine which binds to the CC chemokine
receptor-4 (Imai et al., 1996). It is a Th2 chemokine produced
by dendritic cells, keratinocytes, and endothelial cells of
venules in chronically inflamed skin (Vestergaard et al.,
2000). Chemokine receptor-4 is overexpressed on cutaneous
lymphocyte-associated antigenþ lymphocytes in the skin
and blood (Campbell et al., 1999). Therefore, increased
thymus- and activation-regulated chemokine/CCL17 may be
pivotal in mediating cutaneous fibrosing disease in skin by
recruiting cutaneous lymphocyte-associated antigenþ chemo-
kine receptor-4þ lymphocytes into skin.
Table 5. Growth factor mRNA expression in standardized signal in skin after BMT
BMT control Scl GVHD
Days after BMT 7 30 60 120 7 30 60 120
PDGF-C 465 360 410 449 1,109 1,306 1,156 496
CTGF 1,215 1,384 1,470 1,115 1,475 1,599 2,271 1,196
FGF1 170 114 120 164 272 160 214 133
EGF 176 68 72 65 417 173 271 64
NGF-b 108 0 0 0 109 100 84 45
VEGF-a 0 0 0 90 0 50 99 79
VEGF-b 0 0 0 210 0 399 297 217
G-CSF R 0 76 77 88 280 313 152 89
GM-CSF R 383 171 169 155 1,325 438 328 194
EGF R 304 248 277 587 525 780 395 621
EPO R 522 298 291 415 826 1,546 1,223 449
1BMT, bone marrow transplantation; CTGF, connective tissue growth factor; EGF, epidermal growth factor; EPO, erythropoietin; FGF, fibroblast growth
factor; G-CSF, granulocyte-colony-stimulating factor; mRNA, messenger RNA; NGF, nerve growth factor; PDGF, platelet-derived growth factor; Scl GVHD,
sclerodermatous graft-versus-host disease; VEGF, vascular endothelial growth factor.
Table 6. Cell adhesion molecule mRNA expression in standardized signal in skin after BMT
BMT control Scl GVHD
Days after BMT 7 30 60 120 7 30 60 120
Selectin lymphocyte 0 0 0 0 536 210 173 62
Selectin platelet 0 173 150 149 691 834 710 267
Selectin endothelial 107 41 43 23 900 70 43 34
Integrin alpha 5 0 43 42 57 122 135 115 70
Integrin alpha 6 98 182 170 382 258 727 687 388
Integrin alpha 7 0 0 0 118 132 192 226 139
Integrin alpha 9 0 0 0 0 0 58 54 26
Integrin alpha X 128 0 0 37 196 285 328 75
Integrin alpha V 0 0 0 88 122 283 159 114
ICAM 1 706 374 311 317 1,903 1,166 807 392
VCAM 1 0 0 0 0 370 214 176 0
Cadherin 5 25 34 32 21 0 0 0 0
Cadherin 13 384 211 207 143 168 125 127 110
1BMT, bone marrow transplantation; mRNA, messenger RNA; Scl GVHD, sclerodermatous graft-versus-host disease; VCAM, vascular cell adhesion
molecule.
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Although it is thought that most of the chemokines
contributing to disease in scleroderma belong to the CC
group (Ahmed and Tan, 2003), mRNAs for IFN-g inducible
chemokines, such as CXCL9/Mig, CXCL10/IP-10, CXCL11/
I-TAC, show significant upregulation in skin of Scl GVHD
mice. This group of chemokines belongs to the CXC sub-
family and is strongly associated with Th1-mediated immune
responses. IFN-g inducible chemokines (CXCL9/Mig,
CXCL10/IP-10, and CXCL11/I-TAC) are an exception among
chemokines in that they specifically interact with a single
type of receptor, CXCR3 (Baggiolini, 2003). Increased IFN-g
inducible chemokine mRNA expression has been reported in
thyroid tissue from individuals affected by Hashimoto’s
thyroiditis, in serum of patients with Graves’ disease
(Romagnani et al., 2002) and in Type 1 autoimmune diabetes
(Nicoletti et al., 2002), suggesting a role in inflammation in
early autoimmune disease. Therefore, the high IFN-g envir-
onment in skin in early Scl GVHD is associated with
upregulation of IFN-g inducible chemokines, which may
drive the autoimmune response.
In addition to chemokine mRNA expression, chemokine
receptor mRNAs for CCR1, CCR5, and CCR6 were drama-
tically increased in skin in murine Scl GVHD. All three
chemokine receptors are important in immune cell traffick-
ing, and upregulated CCR6 has been implicated in other
autoimmune diseases. CCR1, which binds to several chemo-
kines, is present at day 7 after BMT in Scl GVHD mice.
Wysocki et al. (2004) showed that in a murine model in
which CCR5-deficient (CCR5/) donor cells were transferred
to non-conditioned haploidentical recipients, there was
reduced donor cell infiltration in liver and lymphoid tissues
compared with transfer of CCR5þ /þ cells. Our data are
consistent with this result. CXCR6 (Bonzo) is expressed by
subsets of Th1 or T-cytotoxic 1 (Tc1) cells, but not by Th2
cells. CXCR6þ T cells are dramatically enriched among
T cells in tissue sites of inflammation, such as rheumatoid
joints and inflamed livers (Kim et al., 2001). CXCR6 may be
important in trafficking of T cells that mediate Th1-type
inflammation.
Therefore, chemokines and their receptors for both T cells
and macrophages appear to be important in autoimmune
fibrosing disease, consistent with data from studies in human
scleroderma and with our previously published results that
T cells and macrophages are both found in early cutaneous
Scl GVHD (Gilliam, 2004). Chemokine receptors may also be
potential targets for therapeutic modulation of Scl GVHD and
related fibrosing diseases.
Growth factors
We examined mRNA expression of several well known
growth factors, which have been reported as characteristic of
human scleroderma: PDGF-C, CTGF, fibroblast growth factor
1, epidermal growth factor, nerve growth factor-b, VEGF-a,
VEGF-b and related receptors (Kahaleh and LeRoy, 1999;
Distler et al., 2001). We found that mRNAs for PDGF,
fibroblast growth factor 1, epidermal growth factor, and nerve
growth factor-b were upregulated at early time points after
BMT in Scl GVHD mice compared to BMT mice. CTGF and
VEGF were increased later. However, there was a modest
increase in mRNA for CTGF in Scl GVHD mice compared
with BMT control mice. Therefore, CTGF may be less
influential in fibrosing disease in this model.
Adhesion molecules
A complex cascade of cytokines and chemokines provides
the road signs for leukocyte migration to skin in cutaneous
inflammation (Schon et al., 2003) and in this Scl GVHD
model, whereas various adhesion molecules orchestrate the
dynamic events of cell–cell and cell–substrate interactions
resulting in cutaneous localization of T cells and macro-
phages (Kluger, 2004). Among the many adhesion-related
genes, we found that mRNAs for L and E selectin (CD62L and
CD62E), L-selectin (selectin lymphocyte), ICAM1, and
vascular cell adhesion molecule 1 were upregulated early
(day 7) after BMT in Scl GVHD mice, during the early
inflammatory phase of cutaneous fibrosis. Certain integrins
were related to later stages of Scl GVHD. E-selectin (selectin
endothelium) is a cell adhesion molecule; its function in
mediating leukocyte rolling is largely redundant with that of
P-selectin (selectin platelet). In addition to mediating
leukocyte rolling, E-selectin (selectin endothelium) partici-
pates in the conversion of rolling to firm adhesion. L-selectin
(selectin lymphocyte), the smallest of the vascular selectins, is
constitutively expressed at the tips of microfolds on granulo-
cytes, monocytes, and a vast array of circulating lymphocytes
(Schon et al., 2003). It is important for lymphocyte homing
and adhesion to high endothelial cells of post-capillary
venules of peripheral lymph nodes. Although the role of
selectins in recruiting immune cells to target organs such as
skin in Scl GVHD is not yet clear, our data suggest that
interference with selectins and their receptor binding may be
useful as a specific immunotherapy for treatment of
scleroderma.
In summary, our gene array study provides an analysis of
the sequential gene expression via mRNA profiles for
immune molecules in skin during the development of murine
Scl GVHD, a model for human scleroderma. Our results are
generally consistent with previously published data in
scleroderma skin, and also identify additional important
genes in early autoimmune fibrosing disease. The temporal
histopathological development of murine cutaneous Scl
GVHD is accompanied by the upregulated expression of
many chemokines and their receptors (CCL2, CCL5, CCL17,
CXCL5, CXCL9, CXCL10, CXCL11, CCR1, CCR5, CXCR6),
cytokines (IFN-g, TNF-b, IL-6, IL-13, TGF-b), growth factors
(PDGF-C, epidermal growth factor, nerve growth factor-b,
VEGF-a, VEGF-b), and adhesion molecules (L-selectin
(selectin lymphocyte), E-selectin (selectin endothelium),
P-selectin (selectin platelet)). A novel finding not reported
previously in sclerodermatous disease is the increased
expression of mRNA for IFN-g inducible chemokines,
most likely a response to the high IFN-g levels in skin in
early disease. The Th1/Th2-like environment changes
over time, from IFN-g high (Th1-like) to IFN-g low, IL10
higher (Th2-like). The disease also progress from
early inflammatory to later non-inflammatory, much like
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scleroderma and localized scleroderma (morphea). This study
provides a foundation for a better understanding of the
pathogenesis of fibrosis and for more effective strategies
for intervention in the development of early scleroderma
and Scl GVHD.
MATERIALS AND METHODS
Generating murine Scl GVHD
Four- to 6-week-old male and female B10.D2 (H-2d) and BALB/c
(H-2d) (Jackson Laboratory, Bar Harbor, ME) mice were used as
donors and recipients, respectively, for BMT to produce Scl GVHD
in a standard method using spleen cells as a source of mature T cells
(6). We have used the male-to-female transplantation to allow
tracking of donor cells in other experiments and to eliminate the
variable of skin injury resulting from caging non-littermate recipient
male mice together. Briefly, female recipient mice were lethally
irradiated with 700 cGy from a Gammacel 137Cs source (J.L.
Shepherd and Associates, San Fernando, CA). Within 6 hours they
were injected by tail vein with male donor bone marrow (1 106/
mouse) and spleen (2 106/mouse) cells suspended in phosphate-
buffered saline (Mediatech, Herndon, VA) with 20 U/ml heparin
(Fisher Scientific, Pittsburgh, PA). A control group of female BALB/c
recipient mice received male BALB/c spleen and bone marrow cells
(syngeneic BMT, referred to as control BMT animals). Animals that
did not engraft died within 10–14 days (radiation control).
Transplanted animals were maintained in sterile MicroIsolator cages
(Lab Products, Seaford, DE) and supplied with autoclaved food and
acidified water. At least three animals per group (Scl GVHD or
control) and per time points of days 7, 30, 60, and 120 post-BMT
were studied in each experiment in three experiments. The weights
of mice were checked each week after BMT. This study was
conducted under the Case Western Reserve University Animal
Resource Center guidelines for humane animal care.
Tissue collection and RNA extraction, preparation, and
characterization
At least three animals (at same ages) per group (experimental and
control BMT) per time point were killed via cervical dislocation at
day 7, 30, 60, and 120 post-BMT. Back skin was chemically
depilated and harvested for buffered formalin fixation (Surgipath
Medical Industries, Richmond, IL), paraffin embedding (Sakura
Finetech, Torrance, CA) routine histology for hematoxylin and eosin
staining and for measurement of skin thickness. The identical
topographical location on dorsums was also collected for RNA
extraction (snap-frozen in liquid nitrogen and stored at 801C). Total
RNA was isolated using TRIzol reagent per manufacturer’s protocol
(GibcoBRL, Carlsbad, CA). RNA quality was assessed by spectro-
photometer at 260/280 nm absorption, and the integrity and overall
quality was evaluated by native agarose gel electrophoresis.
Biotinylated riboprobes synthesized from total RNA specimens were
initially hybridized to an Affimetrix Test3 miniarray (Affymetrix,
Santa Clara, CA) to verify probe quality.
Gene expression analysis
Gene expression was interrogated using Affimetrix Mouse Genome
Arrays 430A, which contain 22,600-oligonucleotide probe sets for
approximately 14,000 well-characterized genes. A representative
mouse from each group (skin thickening, infiltration by inflammatory
cells) was selected for microarray analysis. Analysis was also
performed on skin from a normal mouse. The experiment was
repeated once with another set of transplanted mice at the same time
points with similar results. Total skin RNA was used to prepare
biotinylated target complementary RNA, with minor modifications
from the manufacturer’s recommendations. Eight micrograms of total
RNA was used to generate first-strand complementary DNA by
reverse transcription using a T7-linked oligo(dT) primer. After
second-strand complementary DNA synthesis, in vitro transcription
was preformed with biotinylated uridine triphosphate and cynidine
triphosphate (Enzo Diagnostics, Farmingdale, NY) resulting in the
generation of biotinylated complementary RNA that is approxi-
mately 100-fold amplified above the initial quantity of starting
material. The target biotinylated complementary RNA generated
from each time point was processed as per manufacturer’s
recommendation using an Affymetrix GeneChip instrument system.
Spike transcript control and 15 mg of fragmented complementary
RNA were added to the hybridization cocktail. This mixture was
hybridized to the expression microarray by incubation at 451C
overnight. Arrays were then washed and stained with steptavidin–-
phycoerythrin before being scanned on an Affymetrix GeneChip
scanner. After scanning, array images were assessed by eye to
confirm scanner alignment and the absence of significant bubbles or
scratches on the chip surface. The 30/50 ratios for glyceraldehyde-3-
phosphate dehydrogenase and beta-actin were confirmed to be
within acceptable limits (0.82–1.07), and BioB spike controls
were found to be present on all chips, with BioC, BioD, and CreX
also present in increasing intensity. Finally, each image was scaled
to a target intensity of 1,500 and the scaling factors for all arrays
were confirmed to be within acceptable limits (4.6–7), as were
background and noise.
Data analysis
For Mouse Genome430A arrays, the fluorescent intensity of each
probe was quantified using Microarray Analysis Suite version 5.0
(Affymetrix). The expression level of a single mRNA, defined as the
Signal, was determined by the MAS 5.0 software, which uses a
weighted average fluorescence intensity difference obtained among
the 11–20 probe pairs that interrogate the expression of each
individual gene. This software also makes a detection call (Present
(P), Marginal (M) or Absent (A)) for each gene or probe set, based on
the consistency of the performance of the individual probe pairs, the
hybridization above background, and the signal to noise ratio.
Although fold increase was calculated by signal level change
regardless of detection call, absent (A) signal was treated as zero in
our list table.
Two-way comparisons of the microarray date were also
performed using the MAS 5.0 software. Specifically, changes in
gene expression between Scl GVHD and control samples were
evaluated at each time point. These comparisons in MAS 5.0
provided additional data including the Signal Log Ratio (Fold change
presented in logarithmic form) and the Change Call (Increased (I),
Decreased (D), Marginally Increased (MI), Marginally Decreased
(MD) or No Change (NC)) for each gene being interrogated. The data
were then imported into a Microsoft Excel spreadsheet.
To identify genes that exhibited differences in expression
between Scl GVHD and control groups, the data sets were trimmed
in Excel using the following inclusion criteria. For a gene or a probe
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set to be included in this trimmed data set, it had to display (1) a
Present Call (P) in at least one of the compared samples, and (2) a
Change Call, and a 42-fold difference either increased or decreased
in the expression between the two samples. Addition annotation data
was incorporated into the data set using the Affymetrix Web-based
analysis tool NetAffx.
GeneSpring analysis
The signals displayed for the genes in each sample that were
included in the trimmed data set were imported into GeneSpring
software version 7.2 (Silicon Genetics, San Carlos, CA). To present
the relative expression for a given gene or probe set in each sample,
the measured signal for each probe set was normalized to Sample 1,
which is from normal female BALB/c mouse skin.
One-way hierarchical clustering with Pearson correlation ana-
lyses and minimum distance of 0.001 was employed to order genes
in the trimmed data set for the time course of the two groups. The
resulting gene tree incorporated all the genes that had met inclusion
criteria from the Scl GVHD versus control comparisons at any of the
four time points (7, 30, 60, and 120 days after BMT).
Histologic and morphometric analysis
Formalin-fixed, paraffin-embedded hematoxylin and eosin stained
sections of back skin were scanned with a CCD camera (Axiovision)
using an Axiophot photomicroscope system (C. Zeiss, Oberkochen,
Germany), stored as tiff file, and subjected to image analysis. Dermal
thickening from bottom of the epidermis to fat was evaluated for
each animal as previously described and quantified as ‘‘skin
thickness’’ (McCormick et al., 1999).
Flow cytometry of single cell suspensions
Depilated back skin from five mice/group at day 7 post-BMT (BMT
controls and Scl GVHD) was pooled and digested in Rosewell Park
Memorial Institute media 5% fetal bovine serum containing 500 U/
ml collagenase type 3 (Worthington Biochemical, Lakewood, NJ),
30 U/ml DNase I and 1,000 U/ml hyaluronidase (Worthington) at
371C for 1 hour. Cells were then passed through a 70-mm cell strainer
(Falcon, MA) to generate single cell suspensions. Dead cells and
cellular debris were removed from single cell suspensions by placing
cell suspensions on a discontinuous gradient with Ficoll-Paque
(Pharmacia, Uppsala, Sweden).
Single cell suspensions from skin (approximately 200,000/group)
were incubated on anti-CD3-coated plates for 5–6 hours in Rosewell
Park Memorial Institute media, 5% fetal bovine serum containing
1mg/ml brefeldin A (Golgiplug, BD Bioscience, San Diego, CA).
Anti-CD3 plates were generated by incubating 96 U-bottom plates
with 30/well ml of 100mg/ml solution of anti-CD3 antibody (clone
245–2C11 –ATCC) overnight. Plates were then washed 2 with ice-
cold phosphate-buffered saline before the addition of cells. After
incubation, cells were transferred to 96 V-bottom plates, washed 2
with FACS buffer (phosphate-buffered salineþ 0.1% BSA), incubated
with blocking buffer (10% normal mouse serum (Jackson Immuno-
Research, West Grove, PA) in FACS buffer) for 20 minutes at 41C and
then stained with anti-CD4 conjugated with phycoerythrin-Cy5
(Clone RM4-5, eBioscience, San Diego CA) for an additional
20 minutes. Cells were then fixed with paraformaldehyde and
washed in the presence of saponin (Perm/Wash buffer, BD
Bioscience). Cells (10,000/each antibody) were incubated with
phycoerythrin-labeled anti-cytokine antibodies (for IFN-g, IL-2, IL-4,
IL-10, TNF-a, eBioscience) or appropriate isotype control antibodies
for 15 minutes in the continuing presence of saponin. Cells were
then washed and examined by flow cytometry within 3 hours using
an LSRI flow cytometry (BD) with FlowJo analysis software (Tree Star
Inc, Ashland, OR).
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